SCHEMBL5845145

SCHEMBL5845145

COC(=O)CC(=O)CCc1ccncc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
F2RL1 P55085 1/20 0.53
NAMPT P43490 1/20 0.45
LMNA P02545 2/20 0.44
ALDH1A1 P00352 2/20 0.43
ALOX5 P09917 1/20 0.43
OR51E2 Q9H255 1/20 0.43
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
CYP4F2 P78329 1/20 0.42
CYP4A11 Q02928 1/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
FFAR1 O14842 1/20 0.41
NPY5R Q15761 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
CYP19A1 P11511 1/20 0.41
KDM4E B2RXH2 1/20 0.40
MMP12 P39900 1/20 0.40
MAPT P10636 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3931226 0.87 NAMPT (0.48) F2RL1NAMPTLMNAALDH1A1MEN1
Iodide SCHEMBL20475497 0.86 NAMPT (0.47) F2RL1NAMPTLMNAALDH1A1MEN1
SCHEMBL1259772 0.82 TDP1 (0.56) F2RL1LMNAALDH1A1ALOX5NPC1
SCHEMBL6573723 0.81 FFAR1 (0.52) LMNASMN1; SMN2NPC1RAB9AFFAR1
SCHEMBL6641533 0.81 TSHR (0.48) LMNAALDH1A1KMT2ACYP4F2CYP4A11
SCHEMBL27581983 0.80 MMP12 (0.61) F2RL1LMNAALDH1A1SMN1; SMN2RAB9A
SCHEMBL755111 0.79 F2RL1 (0.57) F2RL1ALOX5OR51E2CYP4F2CYP4A11
SCHEMBL28813051 0.79 F2RL1 (0.57) F2RL1ALDH1A1ALOX5OR51E2CYP4F2
SCHEMBL7178176 0.78 IAPP (0.53) F2RL1NAMPTLMNAALDH1A1SMN1; SMN2
SCHEMBL6646146 0.78 HPGD (0.49) ALDH1A1ALOX5MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7074784-B2 Nitrogen compounds such as methyl 4-(2-chloro-4-fluorophenyl) -2-(3,5-difluoropyridin-2-yl)-6-(4-morpholinylmethyl)-1,4-dihydropyrimidine -5-carboxylate, with mixtures of lamivudine and interferons, used as viricides; hepatitis Goldmann, Siegfried (DE) 2006-07-11 US disclosed
EP-1265889-B1 MEDICAMENTS AGAINST VIRAL DISEASES BAYER HEALTHCARE AG (DE) 2004-06-16 EP disclosed
US-20030232842-A1 Medicaments against viral diseases SUNSHINE LAKE PHARMA CO., LTD. (CN) 2003-12-18 US disclosed
EP-1265889-A1 MEDICAMENTS AGAINST VIRAL DISEASES Bayer Aktiengesellschaft (DE) 2002-12-18 EP disclosed
WO-2001068640-A1 MEDICAMENTS AGAINST VIRAL DISEASES BAYER AKTIENGESELLSCHAFT (DE) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030232842-A1 Medicaments against viral diseases HAVCR2, ENTPD5, TYMP F2RL1 3658/4885NAMPT 145/4885LMNA 3787/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.